TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03407820

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Chromic gut sutures
Description: In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-absorbable Nylon sutures
Description: In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
Study: NCT01127269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
Study: NCT00940108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL425
Description: CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
Study: NCT01892826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: 5000IU
Study: NCT05466773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hemodialysis eating index (HDEI) base education intervention
Description: The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hemodialysis eating index (HDEI) base education intervention
Description: The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hemodialysis eating index (HDEI) base education intervention
Description: The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
Study: NCT01731509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fetal endoscopic tracheal occlusion
Description: FETO will be performed by placing a detachable balloon inside fetal trachea

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fetal endoscopic tracheal occlusion
Description: FETO will be performed by placing a detachable balloon inside fetal trachea
Study: NCT03139357

Intervention type: OTHER
Intervention: GAD7, SF12, medical utilization, helpfulness questionnaire
Description: The questionnaires are administered to track stress level and medical utilization over a 2 year period.
Study: NCT05822778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formaderm Dermal Filler Injection
Description: Dermal filler injection to facial areas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-MED RESTYLANE
Description: Dermal filler injection to facial areas
Study: NCT05437185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
Study: NCT00519311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Intervention Package
Description: CHAP and Ask Diary
Study: NCT02305537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: McLean Anxiety Mastery Program
Description: Cognitive-Behavioral Therapy with Exposure and Response Prevention
Study: NCT01142596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
Study: NCT02976454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Obesity Treatment
Description: Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based behavioral obesity treatment
Description: Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
Study: NCT02019927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal Electrical Stimulation
Description: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal Electrical Stimulation
Description: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal Electrical Stimulation
Description: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study: NCT01999270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)~Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDOPA-PET/MRI imaging
Description: FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
Study: NCT02434939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ketamine
Description: Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
Study: NCT02434939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
Study: NCT03457363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTM will be add above NC
Description: After oxygenation by classical nasal cannula, the DTM will be place above NC
Study: NCT02998463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: skin-to-skin facilitating garment
Description: Fabric garment designed to accommodate term neonates having skin-to-skin contact.
Study: NCT01183806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Exercise training program
Study: NCT03457363

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTM will be add above NC
Description: After oxygenation by classical nasal cannula, the DTM will be place above NC
Study: NCT03872570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: intravenous administration
Study: NCT02859363

Intervention type: GENETIC
Intervention: 26 common Fabry mutation types in Taiwan
Description: Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
Study: NCT01426763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE with rHuPH20

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE with rHuPH20
Study: NCT02926976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone with Clozapine
Description: Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole with Clozapine
Description: Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium valproate with Clozapine
Description: sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified electroconvulsive therapy(MECT) with Clozapine
Description: modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study: NCT00574197

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Sodium
Description: 1440mg/day (720mg by mouth, twice a day)
Study: NCT03713658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone 3 mg
Description: Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 50 mg eq.
Description: Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 75 mg eq.
Description: Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 100 mg eq.
Description: Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 150 mg eq.
Description: Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 175 mg eq.
Description: Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 263 mg eq.
Description: Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 350 mg eq.
Description: Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 525 mg eq.
Description: Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
Study: NCT01084655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.
Study: NCT02926976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic seizure therapy(MST) with Clozapine
Description: Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clozapine
Description: clozapine may be used in the treatment of treatment-resistant schizophrenia
Study: NCT03821389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIOD Frequencer
Description: NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIOD Frequencer
Description: NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.
Study: NCT03275129

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of heart and lungs
Description: Patients will receive an ultrasound assessment of their heart and lungs.
Study: NCT04250441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Transcranial Ultrasound
Description: The FDA has determined that power intensity limits of 720 mW/cm squared at 2 megaHertz is safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion.
Study: NCT00256451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 50 mg/day for two days prior to the alcohol challenge session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg/day for two days prior to the alcohol challenge session

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol
Description: 190 proof alcohol prepared to 11% volume mixed with fruit juice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: alcohol
Description: 190 proof alcohol prepared to 11% volume mixed with fruit juice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham alcohol
Description: non-alcoholic placebo alcohol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham alcohol
Description: non-alcoholic placebo alcohol
Study: NCT04079803

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Oral placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam 100 mg tablet
Description: Simufilam 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam 50 mg oral tablet
Description: Simufilam 50 mg oral tablet
Study: NCT03975166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: 2 inhalations in one study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: 2 inhalations in one study period
Study: NCT03353350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efpeglenatide (SAR439977)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efpeglenatide (SAR439977)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efpeglenatide (SAR439977)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT04660266

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liver Ultrasound
Description: liver ultrasound examination, including gray-scale and seven Doppler examination
Study: NCT03030703

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytic acid
Description: 350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
Study: NCT01525719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg everolimus
Study: NCT04256382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dementia pain care education
Description: Participants are educated about dementia pain care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dementia care education
Description: Participants are educated about dementia pain care.
Study: NCT04572412

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose Radiotherapy
Description: External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.~A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved.
Study: NCT02011087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bioelectric impedance analysis
Description: Undergo bioelectric impedance analysis
Study: NCT04532203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: Each subject receive CAR T-cells by intravenous infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommaya Reservoir
Description: Surgical catheter placement into the fourth ventricle of the brain
Study: NCT01535755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: protocol
Description: In this group, the patients were weaned as the protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: physician's orders
Description: In this group, the patients were weaned as the clinicians' order.
Study: NCT02225951

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional product

Intervention type: OTHER
Group type: OTHER
Intervention: Standard breakfast according to ADA recommendations
Study: NCT01596621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: Bendamustine will be be administered per dose and schedule specified in the arm description.
Study: NCT00839657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm for warfarin
Description: Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical-guided dosing algorithm for warfarin
Description: Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.